Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
Authors:
- 8 September 2015
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 98 (5) , 489-491
Abstract
An early access pathway of conditional approval for potentially beneficial medicines is available within the European regulatory framework. However, marketing authorization does not necessarily result in recommendations for public funding by health technology assessment (HTA) agencies. As conditional approval goes along with less than complete data on benefits and risks of a treatment option for a high medical need, this raises the question how HTA decision‐making is affected by these uncertainties.Keywords
This publication has 3 references indexed in Scilit:
- Use of the conditional marketing authorization pathway for oncology medicines in EuropeClinical Pharmacology & Therapeutics, 2015
- Improving the Contribution of Regulatory Assessment Reports to Health Technology Assessments—A Collaboration between the European Medicines Agency and the European network for Health Technology AssessmentValue in Health, 2014
- Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?Annals of Oncology, 2013